Total-body and myocardial substrate oxidation in congestive heart failure

Metabolism. 1994 Feb;43(2):174-9. doi: 10.1016/0026-0495(94)90241-0.

Abstract

Congestive heart failure is a condition associated with increased plasma norepinephrine levels, which have been demonstrated to impair glucose handling. In the present study, 10 patients suffering from congestive heart failure and 10 healthy age- and body mass index-matched subjects were submitted to a hyperinsulinemic (insulin infusion rate, 0.5 mU/kg.min-1) glucose clamp, while simultaneous D-3H-glucose infusion and indirect calorimetry allowed for determination of glucose turnover parameters and substrate oxidation, respectively. On a separate day, basal local (myocardial) indirect calorimetry was also performed. Our data demonstrate that in congestive heart failure, fasting myocardial glucose oxidation (Gox) was inhibited with a simultaneous increase in lipid oxidation (Lox). In our patients, a significant decrease in total-body insulin-stimulated glucose metabolism (31.0 +/- 0.5 v 20.3 +/- 0.4 mumol/kg.min-1, P < .01) and nonoxidative glucose metabolism (18.9 +/- 1.1 v 11.0 +/- 0.5 mumol/kg.min-1, P < .05) was also found. Such latter changes were also associated with a simultaneous overdrive of Lox (0.4 +/- 0.2 v 1.9 +/- 0.2 mumol/kg.min-1, P < .02) that was correlated with an enhanced availability of plasma free fatty acids (FFAs).

MeSH terms

  • Aged
  • Fasting
  • Fatty Acids, Nonesterified / blood
  • Female
  • Glucose / metabolism
  • Glucose Clamp Technique
  • Heart Failure / metabolism*
  • Hormones / blood
  • Humans
  • Insulin / pharmacology
  • Male
  • Middle Aged
  • Myocardium / metabolism*
  • Oxidation-Reduction

Substances

  • Fatty Acids, Nonesterified
  • Hormones
  • Insulin
  • Glucose